Roche Completes Acquisition of LumiraDx’s Point of Care Technology, Enhancing Global Diagnostic Capabilities

Roche Completes Acquisition of LumiraDx’s Point of Care Technology, Enhancing Global Diagnostic Capabilities

(IN BRIEF) Roche has completed the acquisition of LumiraDx’s Point of Care technology after receiving all necessary antitrust and regulatory clearances. This addition enhances Roche’s diagnostics portfolio with an advanced multi-assay platform that consolidates a wide range of tests, including immunoassay and clinical chemistry, with future potential for molecular testing. The acquisition aims to expand decentralized patient care and improve global access to diagnostic testing, especially in primary care and low- and middle-income countries. Roche will also continue its partnership with the Bill & Melinda Gates Foundation to develop a rapid molecular tuberculosis test, addressing the significant global gap in tuberculosis diagnosis and treatment.

(PRESS RELEASE) BASEL, 29-Jul-2024 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its acquisition of LumiraDx’s Point of Care technology, after securing all necessary antitrust and regulatory approvals. This strategic move allows Roche to incorporate LumiraDx’s innovative multi-assay point of care platform, alongside its R&D, operational, and commercial assets, into its global operations.

The integration of LumiraDx’s technology enhances Roche’s diagnostics portfolio by adding a versatile platform capable of consolidating numerous immunoassay and clinical chemistry tests, with future potential for molecular testing. This will bolster Roche’s capabilities in providing decentralized patient care and expand access to timely diagnostic results globally.

Matt Sause, CEO of Roche Diagnostics, emphasized the significance of this acquisition: “Access to diagnostic testing is critical for healthcare delivery worldwide. We are confident that the LumiraDx platform will help us expand the availability of testing, particularly in primary care settings and low- and middle-income countries.”

Veronique Ameye, CEO of LumiraDx, expressed enthusiasm about joining Roche: “Becoming part of Roche Diagnostics allows us to realize the full potential of our Point of Care technology and increase patient access to community-based healthcare globally. We look forward to continuing our mission to make a greater impact on patient care.”

Roche first announced its intent to acquire LumiraDx’s Point of Care technology in late 2023.

Continued Partnership with the Bill & Melinda Gates Foundation As part of this acquisition, Roche will maintain its collaboration with the Bill & Melinda Gates Foundation. This partnership aims to expand the platform’s molecular diagnostic capabilities, including the development of a rapid point of care molecular tuberculosis test. This initiative addresses the global challenge of undiagnosed and untreated tuberculosis, which affects over 4 million people worldwide. The new, cost-effective test is designed to improve tuberculosis detection and treatment, particularly in remote settings, contributing to global epidemic control efforts.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] World Health Organization (WHO) Global Tuberculosis Report 2022. Accessed 30 May 2024. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022

Media Contacts:

Media Relations:
Phone: +41 61 688 8888
e-mail: media.relations@roche.com

SOURCE: ROCHE